MacroGenics has been granted a patent for compounds targeting IL23A and BAFF, with methods for suppressing inflammatory responses. The patent covers specific polypeptide compositions and nucleic acids. GlobalData’s report on MacroGenics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights MacroGenics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on MacroGenics, Personalized cancer vaccines was a key innovation area identified from patents. MacroGenics's grant share as of January 2024 was 40%. Grant share is based on the ratio of number of grants to total number of patents.

Patent granted for compounds targeting il23a and baff

Source: United States Patent and Trademark Office (USPTO). Credit: MacroGenics Inc

A recently granted patent (Publication Number: US11884744B2) discloses a method for suppressing an inflammatory response in a subject by administering a compound comprising specific polypeptides. The compound includes a first polypeptide with a light chain variable domain of a first immunoglobulin (VL1) specific for a target protein, and a second polypeptide with a light chain variable domain of a second immunoglobulin (VL2) specific for a different target protein. The method involves the association of VL1 and VH1 to form a binding site for the first target protein, and VL2 and VH2 to form a binding site for the second target protein. The compound's structure and amino acid sequences are detailed, with variations in the sequences of the polypeptides provided for different combinations of target proteins.

Furthermore, the patent claims cover additional aspects of the method, such as the inclusion of linkers between the polypeptides, specific amino acid sequences for the linkers, and the association of heavy chain constant regions and light chain constant regions to form a tetravalent molecule. The method aims to address inflammatory conditions and autoimmune conditions in subjects, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, psoriasis, and psoriatic arthritis. The patent provides a detailed framework for the administration of the compound to effectively suppress inflammatory responses in subjects in need of such treatment, offering a novel approach to managing these conditions based on the specific interactions of the polypeptides with target proteins.

To know more about GlobalData’s detailed insights on MacroGenics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies